drugset / Trial / NCT01517724
Bortezomib Consolidation Trial
NaSingle-groupOpen-labelTreatment
Summary
The aim of this trial is to determine whether bortezomib improves response and delays progression for multiple myeloma patients after high dose therapy and autologous stem cell transplant. It will also assess the effect of bortezomib treatment on patient bone health.
Timeline
- Start
- 2009-12
- Primary completion
- 2014-12
- Completion
- 2019-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |